Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 177

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Small Interfering RNA Screens Reveal Enhanced Cisplatin Cytotoxicity in Tumor Cells Having both BRCA Network and TP53 Disruptions

Open access
Bartz, Steven R., Zhang, Zhan, Burchard, Julja, Imakura, Maki, Martin, Melissa, Palmieri, Anthony, Needham, Rachel, Guo, Jie, Gordon, Marcia, Chung, Namjin, Warrener, Paul, Jackson, Aimee L., Carleton, Michael, Oatley, Melissa, Locco, Louis, Santini, Francesca, Smith, Todd, Kunapuli, Priya, Ferrer, Marc, Strulovici, Berta, Friend, Stephen H., Linsley, Peter S. · 2006 · Molecular and Cellular Biology

Abstract

RNA interference technology allows the systematic genetic analysis of the molecular alterations in cancer cells and how these alterations affect response to therapies. Here we used small interfering RNA (siRNA) screens to identify genes that enhance the cytotoxicity (enhancers) of established anticancer chemotherapeutics. Hits identified in drug enhancer screens of cisplatin, gemcitabine, and paclitaxel were largely unique to the drug being tested and could be linked to the drug's mechanism of action. Hits identified by screening of a genome-scale siRNA library for cisplatin enhancers in TP53-deficient HeLa cells were significantly enriched for genes with annotated functions in DNA damage repair as well as poorly characterized genes likely having novel functions in this process. We followed up on a subset of the hits from the cisplatin enhancer screen and validated a number of enhancers whose products interact with BRCA1 and/or BRCA2. TP53(+/-) matched-pair cell lines were used to determine if knockdown of BRCA1, BRCA2, or validated hits that associate with BRCA1 and BRCA2 selectively enhances cisplatin cytotoxicity in TP53-deficient cells. Silencing of BRCA1, BRCA2, or BRCA1/2-associated genes enhanced cisplatin cytotoxicity approximately 4- to 7-fold more in TP53-deficient cells than in matched TP53 wild-type cells. Thus, tumor cells having disruptions in BRCA1/2 network genes and TP53 together are more sensitive to cisplatin than cells with either disruption alone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/mcb.01229-06

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 177

Metadata

Authors
Bartz, S. R., Zhang, Z., Burchard, J., Imakura, M., Martin, M., Palmieri, A., Needham, R., Guo, J., Gordon, M., Chung, N., Warrener, P., Jackson, A. L., Carleton, M., Oatley, M., Locco, L., Santini, F., Smith, T., Kunapuli, P., Ferrer, M., Strulovici, B., Friend, S. H., & Linsley, P. S.
Venue
Molecular and Cellular Biology
Published
2006-12-01
Volume
26
Issue
24
Pages
9377-9386
ISSN
  • 0270-7306 (ISSN-L)
  • 1098-5549
OpenAlex
W2007978156
Cited by
177
References
11
FWCI
9.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.